With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.212327-11-2,7-Bromoquinoxalin-2-amine,as a common compound, the synthetic route is as follows.
7-bromoquinoxaline-2-amine (500 mg, 2.24 mmol) and 2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethan-1-one (462 mg, 2.24 mmol) were added to N-methylpyrrolidone (1 mL). After reaction under agitation at 150 C for 1 h under the protection of nitrogen, the reaction mixture was cooled to rt. Water (10 mL) was added, and EA (20 mL*2) was used for extraction. The organic phases were combined, washed with a saturated saline solution (20 mL*2), dried with anhydrous sodium sulfate, filtered, and concentrated at reduced pressure to obtain a crude compound. Isolation and purification by column chromatography (silica gel, DCM: MeOH = 30:1 as an eluant) was performed to obtain the targeted compound (120 mg, 16.2% yield, yellow solid). LC-MS (ESI): m/z (M+1) 332.14.
212327-11-2, 212327-11-2 7-Bromoquinoxalin-2-amine 15322531, aquinoxaline compound, is more and more widely used in various.
Reference£º
Patent; Impact Therapeutics, Inc; CAI, Suixiong; TIAN, Ye Edward; (74 pag.)EP3567041; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider